According to a research study published in the journal Cancer, Asian women are less likely than non-Hispanic white women to receive timely follow-up after an abnormal screening mammogram.
Being called back after an abnormal mammogram can be a significant source of stress for women. While statistics1 from the American Cancer Society show that less than 10% of women called back for additional tests are found to have breast cancer, delayed follow-up could contribute to poor outcomes. According to a research study published in the journal Cancer,2 Asian women are less likely than non-Hispanic white (NHW) women to receive timely follow-up after an abnormal screening mammogram.
Asian women are often left out of population-based breast cancer studies, and if they are included, they are lumped into a single group. Researchers at the University of California, San Francisco, took a deeper dive into this population to understand its barriers to care. The prospective study used a prospective cohort of 50,970 NHW and Asian women with a Breast Imaging, Reporting and Data System abnormal result of category 0 or 3-plus in the San Francisco Mammography Registry between 2000 and 2010. This information was prospectively gathered by the radiology facilities that the women visited.
The 2 populations were compared based on follow-up care received at 30, 60, and 90 days and no follow-up at 1 year after a radiologic test was performed. Importantly, the Asian group was subcategorized based on their country of origin.
The authors found that within the Asian population, Vietnamese and Filipina women had the longest median time to follow-up imaging tests (32 days and 28 days), while Japanese women had the shortest time (19 days), which was still longer than the median time for NHW women (15 days). A 20% difference was noted in the percentage of NHW women (77%) receiving follow-up at 30 days compared with Asian women (57%; P <.0001). The authors noted that the disparity observed at 30 days held at the 60-day and 90-day time points, although Japanese women were an exception. Filipina women had the highest rate (18.1%) of no follow-up at 1 year among Asians, while the median for the overall Asian population was 15%, compared with 10% for NHWs.
“The reasons for these long delays may be due to linguistic, cultural, and other barriers that affect patient-provider communication for disadvantaged Asian groups,” author Kim Hanh Nguyen, MPH, ScD, said in a statement. “More research attention is needed to understand the specific reasons for these differences.”
Pointing out the diversity within the subgroup of minorities that are classified as Asian, Nguyen added that recognizing these differences may help clinicians develop better rapport and communication with their Asian patients, which can improve adherence to screening recommendations
References
1. Getting called back after a mammogram. American Cancer Society website. https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/mammograms/getting-called-back-after-a-mammogram.html. Accessed June 20, 2017.
2. Nguyen KH, Pasick RJ, Stewart SL, Kerlikowske K, Karliner LS. Disparities in abnormal mammogram follow-up time for Asian women compared with non-Hispanic white women and between Asian ethnic groups [published online June 12, 2017]. Cancer. doi: 10.1002/cncr.30756
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More